Literature DB >> 22802085

Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study.

Pawel Szulc1, Michael Schoppet, Claudia Goettsch, Martina Rauner, Thomas Dschietzig, Roland Chapurlat, Lorenz C Hofbauer.   

Abstract

CONTEXT: Myostatin is expressed mainly in skeletal muscle cells and acts as an inhibitor of muscle growth and differentiation. However, data on the determinants of serum myostatin concentrations in humans are limited.
OBJECTIVE: The aim of the study was to assess the correlates of serum myostatin concentrations in men.
DESIGN: We conducted a cross-sectional analysis of the STRAMBO cohort.
SETTING: Men holding private health insurance coverage with Mutuelle de Travailleurs de la Région Lyonnaise were included in the study. PARTICIPANTS: A total of 1121 male volunteers aged 20-87 yr participated in the study.
INTERVENTIONS: Nonfasting blood samples were collected. MAIN OUTCOME MEASURES: We measured the association of the investigated variables with circulating myostatin levels.
RESULTS: Serum myostatin levels increased slightly with age until 57 yr and then decreased. Circulating myostatin levels showed circannual variation, with the highest concentration in spring. In men older than 57 yr, serum myostatin levels decreased across increasing quartiles of body mass index and of total central and peripheral fat mass (P<0.05 to <0.001). Serum myostatin levels were positively correlated with serum levels of 25-hydroxycholecalciferol (25OHD), even after adjustment for season. Average myostatin levels were 0.47 sd higher in men with 25OHD above 40 ng/ml, compared with those with 25OHD below 20 ng/ml (P<0.05). Current smokers had lower myostatin concentration. Neither current physical activity nor serum levels of PTH, testosterone, and 17β-estradiol were associated with myostatin concentrations.
CONCLUSIONS: In men, circulating myostatin levels show seasonal changes and are associated with age, body mass index, fat mass, smoking, and 25OHD levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22802085     DOI: 10.1210/jc.2012-1273

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Muscle-bone interactions: basic and clinical aspects.

Authors:  Luisella Cianferotti; Maria Luisa Brandi
Journal:  Endocrine       Date:  2013-08-29       Impact factor: 3.633

2.  Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth.

Authors:  Husam Ghanim; Sandeep Dhindsa; Manav Batra; Kelly Green; Sanaa Abuaysheh; Nitesh D Kuhadiya; Antoine Makdissi; Ajay Chaudhuri; Paresh Dandona
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

Review 3.  Vitamin D: Musculoskeletal health.

Authors:  Harjit Pal Bhattoa; Jerzy Konstantynowicz; Natalia Laszcz; Marek Wojcik; Pawel Pludowski
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

4.  Reduced serum myostatin concentrations associated with genetic muscle disease progression.

Authors:  Peter M Burch; Oksana Pogoryelova; Joe Palandra; Richard Goldstein; Donald Bennett; Lori Fitz; Michela Guglieri; Chiara Marini Bettolo; Volker Straub; Teresinha Evangelista; Hendrik Neubert; Hanns Lochmüller; Carl Morris
Journal:  J Neurol       Date:  2017-01-10       Impact factor: 4.849

Review 5.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

Review 6.  Myostatin--the holy grail for muscle, bone, and fat?

Authors:  B Buehring; N Binkley
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

7.  A systematic review of vitamin D status in southern European countries.

Authors:  Yannis Manios; George Moschonis; Christina-Paulina Lambrinou; Konstantina Tsoutsoulopoulou; Panagiota Binou; Alexandra Karachaliou; Christina Breidenassel; Marcela Gonzalez-Gross; Mairead Kiely; Kevin D Cashman
Journal:  Eur J Nutr       Date:  2017-10-31       Impact factor: 5.614

Review 8.  Vitamin D: not just the bone. Evidence for beneficial pleiotropic extraskeletal effects.

Authors:  Massimiliano Caprio; Marco Infante; Matilde Calanchini; Caterina Mammi; Andrea Fabbri
Journal:  Eat Weight Disord       Date:  2016-08-23       Impact factor: 4.652

9.  Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells.

Authors:  Matthew Bowser; Samuel Herberg; Phonepasong Arounleut; Xingming Shi; Sadanand Fulzele; William D Hill; Carlos M Isales; Mark W Hamrick
Journal:  Exp Gerontol       Date:  2012-11-21       Impact factor: 4.032

10.  Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay.

Authors:  H Robert Bergen; Joshua N Farr; Patrick M Vanderboom; Elizabeth J Atkinson; Thomas A White; Ravinder J Singh; Sundeep Khosla; Nathan K LeBrasseur
Journal:  Skelet Muscle       Date:  2015-07-15       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.